THE CHARACTERISTICS OF BLOOD LIPIDS OF MENOPAUSAL WOMEN WITH THE COMPENSATED HYPOTHYROIDISM WHICH RESULTS FROM AUTOIMMUNE THYROIDITIS

Purpose: to study the lipid profile, including of non-high-density lipoproteins cholesterol (non-HDL-C), in postmenopausal women with compensated hypothyroidism. The causes of hypothyroidism included Hashimoto thyroiditis.45 women with hypothyroidism participated in the study (mean ± sd, age (57.4 ± 7.7) years, disease duration (8.0 ± 6.4) years, the duration of postmenopause (6.4 ± 3.5) years). The mean dose of L-T4 (84.3 ± 28.5) μg/d. The control group – 85 women (mean ± sd, age (58.4 ± 5.4) years) no abnormalities of the thyroid gland, as well as other chronic diseases, which could have an impact on lipid metabolism.
The main and control group were matched for age. Average BMI basic group than in controls: (31.6 ± 3.4) and (28.7 ± 4.6) kg/m2 respectively (p = 0.001). Obtained statistical differences in terms of TSH in the study and control groups: 2.15 and 1,22 mU/L (p = 0.001). Upon reaching euthyrosis against the background of hormone replacement therapy with thyroid hormones do not reach the target total cholesterol (TC), low density lipoproteins cholesterol (LDL-C): 5.81 ± 1.14, 3.67 ± 1.06 respectively.
We obtain lower high-density lipoproteins cholesterol (HDL-C) levels in women with drug euthyroidism compared with the control group. Do not get the difference in the values non-HDL-C in the groups studied. In postmenopausal women with compensated hypothyroidism is defined negative correlation ATTPO with HDL-C. Mean values of blood TC, non-HDL-C, LDL-C levels in the groups exceed the optimal ones.

1. Iodine deficiency of a diseases in Russia. Simple solution of a complex problem. G.A. Gerasimov, V.V. Fadeev, N.Yu. Sviridenko et al. Moscow, Adamant Publ., 2002. 168 p. (in Russian).

2. Elimination of Iodine Deficiency Disoders (IDD) in Central and Eastern Europe, the Commonwealth of Independent States, and the Baltic States. F. Delange, F. Robertson, T. VcLoughey, G. Gerasimov. Geneva, WHO/Euro/NUT, 2009. P. 1–168.

3. Kvitkova L.V., Zinchuk S.F., Zatolokina Ye.N. Siberian Medical Journal (Irkutsk), 2009, vol. 84, no. 1, pp. 70–72 (in Russian).

4. Rymar O.D., Mustafina S.V., Simonova G.I., Denisova D.V., Nikitin Yu.P. Clinical and Experimental Tireoidology, 2012, vol. 8, no. 2, pp. 50–54 (in Russian).

5. Mustafina S.V., Rymar O.D., Simonova G.I., Ragino Yu.I., Kuznetsov A.A., Shcherbakova L.V., Malyutina S.K. Atherosclerosis, 2010, vol 6, no. 2, pp. 15–19 (in Russian).

6. Rymar O.D., Mustafin S.V., Simonov G.I., Malyutin S.K., Ragino Yu.I., Shcherbakova L.V., Nikitin Yu.P. Clinical and experimental tireoidology, 2010, vol. 6, no. 4, pp. 34–39 (in Russian).

7. Shin D.J., Osborne T.F. Thyroid hormone regulation and cholesterol metabolism and connected through Sterol Regulatory Element-Blinding Protein. Clin. Endocrinol., 2003, vol. 278, no. 3, pp. 34114–34118.

8. Diekman T., Lansberg P.J., Kastelein J.J. et al. Prevalence and correction of hypothyroidism in a large cohort of patients referred for dyslipidemia. Arch. Intern. Med., 1995, vol. 155, pp. 1490–1495.

9. Allan D. Sniderman, Ken Wiliams et al. Meta-analysis of Low-Density Lipoprotein Cholesterol, non-high-density lipoprotein cholesterol, and Apolipoprotein B as markers of cardiovascular risk. Journal of the American Heart Association. 2011. http://circoutcomes.ahajournals.org/site/subscriptions/ (assessed april 12, 2011).

10. Ito M., Arishima T., Kudo T. Effect of levothyroxine replacement on non-high-density lipoprotein cholesterol in hypothyroid patients. J. Clin. Endocrinol. Metab., 2007, vol. 2, pp. 608–611.

11. Gonca Tame, Meral Mert, Ismet Tamer, Banu Mesci, Damla Kılıc, Safiye Arık. Effects of thyroid autoimmunity on abdominal obesity and hyperlipidaemia. Journal of Endocrinology, 2001, vol. 62, no. 5, pp. 120–123.

12. Belotserkovtseva L.D., Kovalenko L.V., Korneyev E.V. Attending Physician, 2010, no. 3, pp. 25–27 (in Russian).

13. Morgunova T.B. Manuylova Yu.A., Fadeev V.V. Clinical and Experimental tireoidology, 2010, no. 1, p. 54 (in Russian).

14. Franklyn J.A., Daykin J., Betteridge J. et al. Sheppard Thyroxin replacement therapy and circulating lipid concentrations. Clin. Endocrinol., 1993, vol. 38, no. 5, pp. 453–459.

15. Peter P., Mackie Kevin P. Violations of a lipidic exchange: the lane with English. Ed. V. Kukharchuk. Moscow, GEOTAR-media Publ., 2010. 272 p. (in Russian).

16. Russian recommendations of VNOK. Diagnostics and correction of violations of a lipidic exchange with the purpose of prevention and atherosclerosis treatment (the V revision). Atherosclerosis, 2012, vol. 8, no. 2, pp. 61–89 (in Russian).

17. Wiseman S.A., Powell J.T., Humphires S.E., Press M. The magnitude of the hypercholesterolemia of hypothyroidism is assotiated with variation in the low density lipoprotein receptor gene. Clin. Endocrinol. Metab., 1993, vol. 72, no. 1, pp. 108–112.

18. Tsimihodimos V., Bairaktari E., Tzallas C., Miltiadus G., Liberopoulos E., Elisaf M. The incidence of thyroid function abnormalities in patients attending an outpatient lipid clinic. Journal of Endocrinology, 1999, no. 9, pp. 365–368.

19. Leonidas Duntas & Genovefa Kolovou. Options for the treatment of hyperlipidemia in Type 2 diabetes mellitus and hypothyroidism: lowering the cardiovascular risk. Clin. Endocrinol. Metab., 2011, vol. 7, no. 2, pp. 137–144.